middle.news
How Will PainChek Capitalise on FDA Clearance Amid Rising Losses?
2:42pm on Friday 27th of February, 2026 AEDT
•
Healthcare
Read Story
How Will PainChek Capitalise on FDA Clearance Amid Rising Losses?
2:42pm on Friday 27th of February, 2026 AEDT
Key Points
Half-year revenue up 5% to AUD 1.73 million
Loss widened to AUD 4.7 million due to increased marketing and R&D expenses
FDA De Novo clearance granted for Adult App in US long-term care
US reimbursement eligibility via Remote Therapeutic Monitoring unlocked
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Painchek (ASX:PCK)
OPEN ARTICLE